Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
March 27, 2019
Cobra Biologics

Room For Improvement: Tackling Sub-Optimal Downstream Process Unit Operations For Viral Vectors

Earlier this year, BioInsights hosted an expert roundtable featuring Dr Clive Glover (Pall), Dr Damian Marshall (Cell and Gene Therapy Catapult) and Cobra's CSO, Dr Daniel Smith to discuss providing innovation to viral vector bioprocessing if AAV vector supply is to meet increasing demand.

Room For Improvement: Tackling Sub-Optimal Downstream Process Unit Operations For Viral Vectors

Earlier this year, BioInsights hosted an expert roundtable featuring Dr Clive Glover (Pall), Dr Damian Marshall (Cell and Gene Therapy Catapult) and Cobra's CSO, Dr Daniel Smith to discuss providing innovation to viral vector bioprocessing if AAV vector supply is to meet increasing demand.

-
Cobra Biologics
-
March 27, 2019

Earlier this year, BioInsights hosted an expert roundtable featuring Dr Clive Glover (Pall), Dr Damian Marshall (Cell and Gene Therapy Catapult) and Cobra's CSO, Dr Daniel Smith to discuss providing innovation to viral vector bioprocessing if AAV vector supply is to meet increasing demand.

The key questions include:

  • How to overcome the particular challenges in AAV downstream analytics development?
  • How to improve the chromatography step in particular?
  • How and where can these initiatives and methodologies be repurposed to benefit the lentiviral vector field?  

Click here to read the interview, or if you would prefer to listen to the podcast, click here.

Pictured: Daniel Smith, CSO, Cobra Biologics

Last updated:
March 27, 2019

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Earlier this year, BioInsights hosted an expert roundtable featuring Dr Clive Glover (Pall), Dr Damian Marshall (Cell and Gene Therapy Catapult) and Cobra's CSO, Dr Daniel Smith to discuss providing innovation to viral vector bioprocessing if AAV vector supply is to meet increasing demand.

The key questions include:

  • How to overcome the particular challenges in AAV downstream analytics development?
  • How to improve the chromatography step in particular?
  • How and where can these initiatives and methodologies be repurposed to benefit the lentiviral vector field?  

Click here to read the interview, or if you would prefer to listen to the podcast, click here.

Pictured: Daniel Smith, CSO, Cobra Biologics

Last updated:
March 27, 2019

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail